CorMedix Inc.
CRMDAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | Les Sulewski | $15.00(+93%) | $7.78 | TheFly |
| Apr 28, 2026 | RBC Capital | Leonid Timashev | $14.00(+79%) | $7.82 | TheFly |
| Mar 6, 2026 | Leerink Partners | Roanna Ruiz | $13.00(+101%) | $6.46 | StreetInsider |
| Jan 23, 2026 | H.C. Wainwright | $13.00(+75%) | $7.44 | TheFly | |
| Jan 21, 2026 | RBC Capital | $13.00(+89%) | $6.88 | TheFly | |
| Jan 8, 2026 | Truist Financial | $16.00(+115%) | $7.44 | TheFly | |
| Oct 21, 2025 | RBC Capital | Gregory Renza | $22.00(+81%) | $12.16 | TheFly |
| Aug 8, 2025 | H.C. Wainwright | Brandon Folkes | $17.00(+65%) | $10.33 | TheFly |
| Mar 13, 2024 | RBC Capital | Gregory Renza | $9.00(+131%) | $3.90 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Needham | maintain | Buy | Nov 2, 2026 |
| Needham | maintain | Buy | Oct 19, 2026 |
| RBC Capital | maintain | Outperform | Aug 14, 2026 |
| RBC Capital | maintain | Outperform | Jul 7, 2026 |
| RBC Capital | maintain | Outperform | Apr 28, 2026 |
| Citizens | maintain | Market Outperform | Apr 28, 2026 |
| Leerink Partners | maintain | Outperform | Apr 28, 2026 |
| Needham | maintain | Buy | Apr 27, 2026 |
| D. Boral Capital | maintain | Buy | Apr 27, 2026 |
| Needham | maintain | Buy | Mar 5, 2026 |
| D. Boral Capital | maintain | Buy | Feb 11, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 23, 2026 |
| RBC Capital | maintain | Outperform | Jan 21, 2026 |
| D. Boral Capital | maintain | Buy | Jan 8, 2026 |
| Needham | maintain | Buy | Jan 8, 2026 |
| D. Boral Capital | maintain | Buy | Dec 18, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 13, 2025 |
| D. Boral Capital | maintain | Buy | Nov 12, 2025 |
| Needham | maintain | Buy | Nov 12, 2025 |
| RBC Capital | maintain | Outperform | Oct 21, 2025 |
| D. Boral Capital | upgrade | Hold →Buy | Oct 20, 2025 |
| JMP Securities | maintain | Market Outperform | Sep 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 8, 2025 |
| D. Boral Capital | downgrade | Buy →Hold | Jun 30, 2025 |
| Needham | maintain | Buy | Jun 24, 2025 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.09| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $0.29 | $0.24 | $101.9M | $96.0M |
| May 14, 2026 | $0.43 | $0.35 | $127.4M | $105.0M |
| Mar 5, 2026 | $0.18 | $0.86 | $128.6M | $127.0M |
| Nov 12, 2025 | $0.57 | $0.48 | $104.3M | $86.0M |
| Aug 7, 2025 | $0.28 | $0.20 | $39.7M | $42.5M |
| May 6, 2025 | $0.30 | $0.25 | $39.1M | $29.9M |
| Mar 25, 2025 | $0.22 | $0.17 | $31.2M | $31.3M |
| Oct 30, 2024 | $-0.05 | $-0.10 | $11.5M | $19.8M |
News
PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 12, 2026, and will host a corporate update conference call at 8:30 a.m. Eastern Standard Time.
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to discuss the Company's complete quarterly financial performance.
CorMedix (NASDAQ: CRMD - Get Free Report) and MediciNova (NASDAQ: MNOV - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation. Valuation and Earnings This table compares CorMedix and MediciNova"s
PARSIPPANY, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) seeking approval of REZZAYO® (rezafungin for injection) for the prophylaxis of invasive fungal disease. The sNDA was submitted by Mundipharma, CorMedix's global development partner, and the FDA has granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target ac…
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of Matt David, M.D., as Chief Financial Officer.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CorMedix (CRMD) and Prothena (PRTA). But which of these two stocks offers value investors a better bang for their buck right now?
The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8 – 10, 2026.
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.
CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript
CorMedix NASDAQ: CRMD reported second-quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, while reaffirming its full-year revenue outlook and raising adjusted EBITDA guidance. The company also said it signed a multiyear commercial supply agreement for DefenCath with an additional large dialysis organization, giving it supply agreements with each of the five largest U.S. dialysis providers.
CorMedix Inc. (NASDAQ:CRMD) shares are rising on Thursday after the company reported strong second-quarter results. The broader market was also slightly higher, with S&P 500 futures up 0.2%.
CorMedix (CRMD) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.28 per share a year ago.
‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J.